{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:19:41Z","timestamp":1761920381282},"reference-count":24,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>ABSTRACT The perception of multiple sclerosis (MS) severity and risk associated with therapies might influence shared decision making in different countries. We investigated the perception of MS severity and factors associated with risk acceptance in Brazil in 96 patients with relapsing-remitting MS using a standardized questionnaire and compared this with two European cohorts. Multiple sclerosis was perceived as a very severe disease and the risk of developing progressive multifocal leukoencephalopathy due to natalizumab was seen as moderate to high. Seventy-six percent considered a risk of 1:1,000, or higher, an impediment for natalizumab use. Older age was the only variable associated with higher risk acceptance and our patients showed a more conservative profile than German and Spanish patients. Our patients perceived MS severity and progressive multifocal leukoencephalopathy risk similarly to elsewhere, but their willingness to take risks was more conservative. This should be considered when discussing therapeutic options and it might have an impact on guideline adaptations.<\/jats:p>","DOI":"10.1590\/0004-282x20170167","type":"journal-article","created":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T19:00:32Z","timestamp":1516474832000},"page":"6-12","source":"Crossref","is-referenced-by-count":5,"title":["Multiple sclerosis risk perception and acceptance for Brazilian patients"],"prefix":"10.1590","volume":"76","author":[{"given":"Denis Bernardi","family":"Bichuetti","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Azze","family":"Franco","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Elias","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia C. R.","family":"Mendon\u00e7a","sequence":"additional","affiliation":[{"name":"Universidade Federal de Goi\u00e1s,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine Fiama Diniz","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Universidade Federal de Goi\u00e1s,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise Sisterolli","family":"Diniz","sequence":"additional","affiliation":[{"name":"Universidade Federal de Goi\u00e1s,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Tur","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona,  Spain; University College London,  United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Tintor\u00e9","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona,  Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enedina Maria Lobato de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"1076","key":"ref1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi G","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/01.wnl.0000218309.01322.5c","article-title":"Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States","volume":"66","author":"Kobelt G","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/0004-282x20160185","article-title":"Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology","volume":"75","author":"Comini-Frota ER","year":"2017","journal-title":"Arq Neuropsiquiatr"},{"issue":"1-2","key":"ref4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jns.2013.02.018","article-title":"Patient autonomy in multiple sclerosis: possible goals and assessment strategies","volume":"331","author":"Heesen C","year":"2013","journal-title":"J Neurol Sci"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458509104591","article-title":"Measures in the first year of therapy predict the response to interferon beta in MS","volume":"15","author":"R\u00edo J","year":"2009","journal-title":"Mult Scler."},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0317167100014244","article-title":"Treatment optimization in MS: Canadian MS Working Group updated recommendations","volume":"40","author":"Freedman MS","year":"2013","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u2018no evidence of disease activity\u2019 in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel M","year":"2015","journal-title":"Ther Adv Neurol Disorder"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14737175.2016.1217155","article-title":"Perception of risk and shared decision making process in multiple sclerosis","volume":"17","author":"Cocco E","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"1-2","key":"ref9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2010.09.012","article-title":"Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement","volume":"306","author":"Heesen C","year":"2011","journal-title":"J Neurol Sci"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1352458512439238","article-title":"Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision","volume":"18","author":"Tur C","year":"2012","journal-title":"Mult Scler."},{"issue":"2","key":"ref11","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan C","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1177\/1352458510379819","article-title":"Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists","volume":"16","author":"Heesen C","year":"2010","journal-title":"Mult Scler."},{"issue":"12","key":"ref13","article-title":"Risk acceptance in multiple sclerosis patients on natalizumab treatment","volume":"8","author":"Tur C","year":"2013","journal-title":"PLoS One"},{"key":"ref14","article-title":"Portaria n\u00ba 1.505, de 29 de dezembro de 2014. Aprova o Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Esclerose M\u00faltipla","year":"2014","journal-title":"Di\u00e1rio Oficial Uni\u00e3o"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke JF","year":"1983","journal-title":"Neurology"},{"key":"ref16","series-title":"NEO PI-R: Invent\u00e1rio de personalidade Neo revisado; e Invent\u00e1rio de cinco fatores Neo revisado: NEO-FFI-R (vers\u00e3o curta)","author":"Costa Junior PT","year":"2010"},{"key":"ref17","series-title":"Applied multivariate statistical analysis","author":"Johnson RA","year":"2002","edition":"5th"},{"key":"ref18","series-title":"An introduction to applied multivariate analysis","author":"Raykov T","year":"2012"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jpsychores.2010.12.010","article-title":"Personality traits in multiple sclerosis: association with mood and anxiety disorders","volume":"70","author":"Bruce JM","year":"2011","journal-title":"J Psychosom Res"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3999(02)00332-X","article-title":"Correlates of illness worry in chronic fatigue syndrome","volume":"54","author":"Taillefer SS","year":"2003","journal-title":"J Psychosom Res"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.msard.2015.03.003","article-title":"Risk tolerance to MS therapies: Survey results from the NARCOMS registry","volume":"4","author":"Fox RJ","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman CH","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0404.2003.00157.x","article-title":"Cognitive impairment in patients suffering from relapsing-remitting multiple sclerosis with EDSS < or = 3.5","volume":"108","author":"Ruggieri RM","year":"2003","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/nmt.14.12","article-title":"Aging with multiple sclerosis: cognitive, emotional and neuropathological considerations","volume":"4","author":"Gray V","year":"2014","journal-title":"Neurodegener Dis Manag"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v76n1\/0004-282X-anp-76-1-0006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T19:00:36Z","timestamp":1516474836000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2018000100006&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0004-282X2018000100006"],"URL":"https:\/\/doi.org\/10.1590\/0004-282x20170167","relation":{},"ISSN":["1678-4227","0004-282X"],"issn-type":[{"value":"1678-4227","type":"electronic"},{"value":"0004-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}